What is Lantern Pharma's gross profit margin?

What is the market's earnings forecast for Lantern Pharma next quarter?

What is Lantern Pharma's latest dividend and current dividend yield?

What were the key takeaways from Lantern Pharma’s earnings call?

What guidance did Lantern Pharma's management provide for the next earnings period?

Did Lantern Pharma beat or miss consensus estimates last quarter?

What does Lantern Pharma do and what are its main business segments?

What were the key takeaways from Lantern Pharma's earnings call?

- **AI Spin-off Success:** Launch of Open-Medicine AI targets $10B AI drug discovery market, with early user adoption and pharma interest.
- **Clinical Milestones:** LP-300 shows 8.4-month PFS in L858R patients; LP-184 gains FDA clearance for triple-negative breast cancer trial.
- **Financial Discipline:** 25% YoY operating expense reduction, despite $7.1M net loss driven by one-time warrant expense.
- **Pediatric Innovation:** STAR-001 spironolactone trial for rare pediatric cancers aims for compassionate use and trial launches.

**【CEO Opening Remarks】**
- Announced the establishment of Open-Medicine AI (OMAI), a separate company commercializing Lantern's AI platform, with the goal of becoming a standalone entity. OMAI aims to disrupt the $10 billion AI drug discovery market by 2030.
- Highlighted disciplined execution with a 25% year-over-year reduction in operating expenses, despite advancing multiple clinical programs and launching OMAI.
- Emphasized the dual growth engines: a clinically validated drug pipeline and an AI platform with potential standalone value.

**【CEO Discussion of Key Programs】**
- **LP-300 (Lung Cancer):** Phase II HARMONIC trial showed median PFS of 8.4 months in L858R patients, with 77% clinical benefit rate. Protocol amended to focus on L858R patients, extending treatment to 8 cycles, and transitioning to a single-arm design. Enrollment underway in the U.S. and Taiwan.
- **LP-184 (Triple-Negative Breast Cancer):** FDA-cleared phase I-B/II trial for relapsed/refractory patients. Received patent allowance for patient selection biomarkers, with 63-patient trial showing tumor reduction in DNA repair-deficient patients.
- **Pediatric Oncology (STAR-001):** Preclinical data supports spironolactone's ability to degrade ERCC3 protein, targeting rare pediatric brain tumors. Seeking compassionate use and trial partnerships.

**【CFO Financial Commentary】**
- **Cash Position:** $7.4 million as of June 30, 2026, down from $10.1 million at year-end due to a $4.4 million registered direct offering in May.
- **Operating Expenses:** R&D decreased 42% to $1.8 million, G&A increased 8% to $1.7 million, driven by business development and investor relations.
- **Net Loss:** $7.1 million ($0.57 per share) due to a $3.6 million non-cash expense from warrant fair value adjustments, compared to $4.3 million ($0.40 per share) in Q2 2025.

**【Q&A Highlights】**
- **LP-300 Enrollment:** 15-16 patients expected to be enrolled under the new protocol over 4-6 months, with updates anticipated by year-end.
- **OMAI Adoption:** Early users find the platform sticky, particularly for generative chemistry and biocomputational tools. Pharma interest is growing, with several companies exploring partnerships.
- **Shareholder Benefits:** OMAI may distribute shares to Lantern shareholders as it raises capital and moves toward public listing, maintaining Lantern as a major shareholder.

LTRN

LTRN

Lantern Pharma (LTRN) Financials Overview

LTRN Q2 2026 Earnings

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Income Statement

Trend

Breakdown

Balance Sheet

Trend

Breakdown

Cash Flow

Trend

Breakdown

Revenue Breakdown

By Business

By Region

Dividend

Payout Ratio

Dividend Yield

You can ask Aime